Medicenna Therapeutics Corp. MDNAF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.79% | -12.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.21% | 5.35% | |||
| Operating Income | 7.21% | -5.35% | |||
| Income Before Tax | -18.96% | 1.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.96% | 1.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.96% | 1.40% | |||
| EBIT | 7.21% | -5.35% | |||
| EBITDA | 7.26% | -5.38% | |||
| EPS Basic | -14.59% | 1.33% | |||
| Normalized Basic EPS | -14.72% | 1.70% | |||
| EPS Diluted | -14.59% | 1.33% | |||
| Normalized Diluted EPS | -14.72% | 1.70% | |||
| Average Basic Shares Outstanding | 3.87% | 0.00% | |||
| Average Diluted Shares Outstanding | 3.87% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||